Drug Research
eTheRNA advances in-vivo mRNA cancer immunotherapy into first oncology clinical studies
eTheRNA immunotherapies, a clinical-stage company developing mRNA based cancer immunotherapies from its unique TriMix platform, announces the start of the first Phase Ib oncology clinical study evaluating its novel candidate TriMix-MEL (ECI-006) in metastatic melanoma patients showing no evidence...
Drug Research
Eisai Temporarily Withdraws New Drug Application for Anticancer Agent Halaven in China
Eisai Co., Ltd. announced today that, in alignment with Chinese regulations, it has temporarily withdrawn its new drug application for anticancer agent eribulin mesylate (Brand name: Halaven) in China in order to submit additional documentation. No...
Drug Research
Sandoz receives approval in Europe for Rixathon® to treat blood cancers and immunological diseases
Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, announced today that the EC  has approved Rixathon® (biosimilar rituximab*) for use in Europe**. Rixathon is approved for use in all indications of the reference medicine, MabThera®...
Drug Research
Numerate and Takeda Enter Agreement to Generate Novel Clinical Candidates Using AI-Driven Drug Discovery
Numerate, Inc., a computational drug design company applying artificial intelligence (AI) at cloud scale to transform small molecule drug discovery, announced the formation of a multi-year agreement with Takeda Pharmaceutical Company Limited under which Numerate will identify and deliver...
Drug Research
Eisai Enters Into Joint Research Agreement With The Broad Institute To Develop An Antimalarial Medicine
Eisai Co Ltd announced that it has entered into a new joint research agreement with the Broad Institute , a collaborative research institute which includes researchers from the Massachusetts Institute of Technology and Harvard University to develop a new...
Drug Research
OBI Pharma to develop OBI-3424 (previously TH-3424) as a potential treatment of cancers expressing AKR1C3
OBI Pharma, Inc., a Taiwan biopharma company announced an agreement with Threshold Pharmaceuticals, Inc. to acquire TH-3424, a first-in-class novel small-molecule prodrug that selectively targets cancers overexpressing the enzyme aldo-keto reductase 1c3 (AKR1C3). The product will...
Articles
Organs-On-Chips To Revolutionize The Drug Development Industry
The market for organs-on-chips (OOCs), the cell culture chips that imitate the activities, mechanisms and responses of organs, will be worth $284 millionby 2021, according to research from The Business Research Company in its report Organ-On-Chip (OOC) Global Market...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read